| Index | NDX, S&P 500 | P/E | 20.71 | EPS (ttm) | 3.45 | Insider Own | 20.43% | Shs Outstand | 451.69M | Perf Week | 2.70% |
| Market Cap | 32.27B | Forward P/E | 13.14 | EPS next Y | 5.44 | Insider Trans | 0.11% | Shs Float | 450.24M | Perf Month | 7.64% |
| Enterprise Value | 40.26B | PEG | 2.00 | EPS next Q | - | Inst Own | - | Short Float | 4.11% | Perf Quarter | 16.90% |
| Income | 1.59B | P/S | 1.59 | EPS this Y | 8.21% | Inst Trans | - | Short Ratio | 4.50 | Perf Half Y | 3.81% |
| Sales | 20.24B | P/B | 2.94 | EPS next Y | 10.44% | ROA | 4.27% | Short Interest | 18.52M | Perf YTD | -12.89% |
| Book/sh | 24.33 | P/C | 15.33 | EPS next 5Y | 10.35% | ROE | 15.16% | 52W High | 89.77 -20.41% | Perf Year | -6.16% |
| Cash/sh | 4.66 | P/FCF | 36.06 | EPS past 3/5Y | 2.54% 0.63% | ROIC | 8.15% | 52W Low | 58.75 21.62% | Perf 3Y | 9.54% |
| Dividend Est. | 0.16 (0.22%) | EV/EBITDA | 13.10 | Sales past 3/5Y | 3.99% 3.74% | Gross Margin | 42.90% | Volatility | 2.32% 2.40% | Perf 5Y | - |
| Dividend TTM | 0.18 (0.25%) | EV/Sales | 1.99 | EPS Y/Y TTM | -20.51% | Oper. Margin | 12.70% | ATR (14) | 1.73 | Perf 10Y | - |
| Dividend Ex-Date | Oct 23, 2026 | Quick Ratio | 0.72 | Sales Y/Y TTM | 2.90% | Profit Margin | 7.86% | RSI (14) | 64.57 | Recom | 2.42 |
| Dividend Gr. 3/5Y | - | Current Ratio | 1.02 | EPS Q/Q | 6.60% | SMA20 | 5.95% | Beta | 0.67 | Target Price | 78.80 |
| Payout | 4.02% | Debt/Eq | 0.94 | Sales Q/Q | 5.77% | SMA50 | 4.52% | Rel Volume | 0.82 | Prev Close | 71.42 |
| Employees | 54,000 | LT Debt/Eq | 0.90 | Earnings | Oct 28 | SMA200 | 1.89% | Avg Volume | 3.62M | Price | 71.45 |
| IPO Date | Dec 15, 2022 | Option/Short | Yes / Yes | EPS/Sales Surpr. | 9.08% 0.59% | Net Debt/EBITDA | 2.60 | Volume | 2,975,973 | Change | 0.04% |
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Oct-06-26 | Initiated | Barclays | Overweight | $78 → $85 |
| Sep-22-26 | Initiated | Needham | Buy | $93 |
| Jul-30-26 | Reiterated | Evercore ISI Group | Outperform | $80 → $84 |
| Jul-29-26 | Reiterated | BTIG | Buy | $75 → $79 |
| Jul-16-26 | Reiterated | UBS | Neutral | $69 → $67 |
| Jul-13-26 | Reiterated | BTIG | Buy | $80 → $75 |
| Jul-08-26 | Initiated | BMO Capital | Market Perform | $70 |
| Jun-23-26 | Initiated | RBC Capital | Outperform | $80 |
| May-21-26 | Upgrade | UBS | Sell → Neutral | $77 → $69 |
| Apr-30-26 | Reiterated | Oppenheimer | Outperform | $89 → $85 |
GE HealthCare Technologies Inc. is a global medical technology company that creates, manufactures, and markets a diverse range of medical devices, services, and integrated digital solutions. These offerings are designed to assist in the diagnosis, treatment, and ongoing monitoring of patients. The company boasts an extensive international presence, serving markets across the United States, Canada, Europe, the Middle East, Africa, China, Taiwan, Mongolia, and Hong Kong, among other regions. Its operations are structured across four primary business divisions: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics. The Imaging division specializes in advanced diagnostic imaging technologies, including systems for molecular imaging, Computed Tomography (CT) scans, Magnetic Resonance (MR) imaging, image-guided therapy, and X-ray, alongside specialized women's health products. The Ultrasound segment delivers a comprehensive suite of ultrasound solutions utilized for the screening, diagnosis, treatment, and monitoring of various diseases. These applications span radiology, primary care, women's health, cardiovascular diagnostics, point-of-care, and portable handheld devices, in addition to products supporting surgical visualization and guidance. The Patient Care Solutions segment is dedicated to providing essential medical devices, consumable products, services, and digital platforms. Its portfolio encompasses patient monitoring, anesthesia delivery and respiratory care, diagnostic cardiology, and maternal-infant care products. The Pharmaceutical Diagnostics segment supplies specialized diagnostic agents to the radiology and nuclear medicine industries. These include contrast media pharmaceuticals, administered to patients prior to scans like CT, angiography, X-ray, and MR, to enhance the visibility of internal tissues and structures. It also offers molecular imaging agents, or radiopharmaceuticals – molecular tracers labeled with radioisotopes – injected into patients for advanced diagnostic imaging applications such as Single-Photon Emission Computed Tomography (SPECT), Positron Emission Tomography (PET), and specific ultrasound procedures. Established in 2022, GE HealthCare Technologies Inc. maintains its corporate headquarters in Chicago, Illinois.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 20,243 | 20,625 | 19,672 | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 11,556 | 12,378 | 11,467 | — | — | — | — | — | |
| Gross Profit | 8,685 | 8,247 | 8,205 | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 4,316 | 4,225 | 4,269 | — | — | — | — | — | |
| Research and Development | 1,322 | 1,260 | 1,311 | — | — | — | — | — | |
| Other Operating Expense | 478 | 0 | 0 | — | — | — | — | — | |
| Operating Income | 2,571 | 2,762 | 2,625 | — | — | — | — | — | |
| Interest Expense | 436 | 450 | 505 | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | -92 | 456 | 461 | — | — | — | — | — | |
| Net Income Before Taxes | 2,043 | 2,768 | 2,581 | — | — | — | — | — | |
| Income Taxes | 446 | 614 | 531 | — | — | — | — | — | |
| Consolidated Net Income | 1,592 | 2,084 | 1,993 | — | — | — | — | — | |
| Net Income From Continuing Operations | 1,597 | 2,154 | 2,050 | — | — | — | — | — | |
| Net Income | 1,592 | 2,084 | 1,993 | — | — | — | — | — | |
| EPS (Recurring) | 3.48 | 4.56 | 4.37 | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | 3.48 | 4.56 | 4.37 | — | — | — | — | — | |
| EPS (Diluted) | 3.45 | 4.55 | 4.34 | — | — | — | — | — | |
| EBITDA | 3,073 | 3,785 | 3,666 | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | 20.71 | 18.03 | 18.01 | — | — | — | — | — | |
| Price To Sales Ratio | 1.60 | 1.82 | 1.81 | — | — | — | — | — | |
| Gross Margin | 42.90 | 39.99 | 41.71 | — | — | — | — | — | |
| Operating Margin | 12.70 | 13.39 | 13.34 | — | — | — | — | — | |
| Net Margin | 7.86 | 10.10 | 10.13 | — | — | — | — | — | |
| Shares Outstanding | 453 | 457 | 456 | — | — | — | — | — | |
| Market Capitalization | 32,367 | 37,483 | 35,650 | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — |
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Lobo Kevin | Director | May 22 '26 | Buy | 64.18 | 10,000 | 641,800 | 14,363 | May 26 |
| Hochman Rodney F | Director | May 12 '26 | Buy | 62.03 | 1,618 | 100,365 | 1,618 | May 13 |
| Yang Watkin Phoebe L. | Director | May 08 '26 | Buy | 63.01 | 1,000 | 63,006 | 13,702 | May 11 |
| CULP H LAWRENCE JR | Director | May 06 '26 | Buy | 61.88 | 80,805 | 5,000,076 | 151,207 | May 07 |
| Stromberg William J | Director | May 06 '26 | Buy | 61.69 | 1,000 | 61,689 | 15,330 | May 07 |
| SACCARO JAMES | Chief Financial Officer | May 01 '26 | Buy | 60.60 | 3,310 | 200,585 | 87,471 | May 01 |
| Jimenez Frank R | GC & Corporate Secretary | Apr 30 '26 | Buy | 60.45 | 1,750 | 105,788 | 93,932 | Apr 30 |
| Arduini Peter J | President and CEO | Apr 30 '26 | Buy | 59.92 | 4,169 | 249,827 | 259,424 | Apr 30 |
| Rott Roland | CEO, Imaging | Sep 11 '25 | Option Exercise | 55.91 | 5,341 | 298,592 | 32,128 | Sep 12 |
| Newcomb George A. | Chief Accounting Officer | Feb 18 '25 | Sale | 92.54 | 2,000 | 185,080 | 7,462 | Feb 19 |
| Rott Roland | CEO, Imaging | Nov 06 '24 | Sale | 86.48 | 3,577 | 309,339 | 24,298 | Nov 06 |
| Rott Roland | CEO, Imaging | Nov 05 '24 | Option Exercise | 40.40 | 13,275 | 536,310 | 37,573 | Nov 06 |
| Rackliffe Philip | CEO, AVS | Nov 05 '24 | Sale | 87.63 | 900 | 78,867 | 12,715 | Nov 05 |
| Stacherski Kenneth R. | Ch. Supply Chain & Serv. Ofc. | Aug 14 '24 | Sale | 83.22 | 19,008 | 1,581,846 | 38,541 | Aug 15 |
| Westrick Thomas J. | CEO, Patient Care Solutions | Aug 07 '24 | Sale | 80.78 | 2,750 | 222,145 | 17,509 | Aug 07 |